Format

Send to

Choose Destination
Cell Mol Life Sci. 2005 Aug;62(15):1671-81.

Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.

Author information

1
Division of Nephrology, Vanderbilt University Medical Center, S-3223 MCN, 1161 21st Avenue South, Nashville, Tennessee 37232-2372, USA. paul.voziyan@vanderbilt.edu

Abstract

The discovery that pyridoxamine (PM) can inhibit glycation reactions and the formation of advanced glycation end products (AGEs) stimulated new interest in this B6 vitamer as a prospective pharmacological agent for treatment of complications of diabetes. The mechanism of action of PM includes: (i) inhibition of AGE formation by blocking oxidative degradation of the Amadori intermediate of the Maillard reaction; (ii) scavenging of toxic carbonyl products of glucose and lipid degradation; and (iii) trapping of reactive oxygen species. The combination of these multiple activities along with PM safety posture it as a promising drug candidate for treatment of diabetic complications as well as other multifactorial chronic conditions in which oxidative reactions and carbonyl compounds confer pathogenicity.

PMID:
15905958
DOI:
10.1007/s00018-005-5082-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center